Other Non-Current Liabilities
Regeneron Pharmaceuticals Other Non-Current Liabilities increased by 5.3% to $2.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 27.0%, from $1.67B to $2.13B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 24.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $596.30M | $662.60M | $680.20M | $692.50M | $724.70M | $598.60M | $638.00M | $677.30M | $716.80M | $832.40M | $854.10M | $908.50M | $1.46B | $1.54B | $1.57B | $1.67B | $1.70B | $1.86B | $2.02B | $2.13B |
| QoQ Change | — | +11.1% | +2.7% | +1.8% | +4.6% | -17.4% | +6.6% | +6.2% | +5.8% | +16.1% | +2.6% | +6.4% | +61.1% | +5.5% | +1.8% | +6.6% | +1.6% | +9.4% | +8.4% | +5.3% |
| YoY Change | — | — | — | — | +21.5% | -9.7% | -6.2% | -2.2% | -1.1% | +39.1% | +33.9% | +34.1% | +104.1% | +85.4% | +84.0% | +84.3% | +16.3% | +20.6% | +28.5% | +27.0% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's other non-current liabilities?
- Regeneron Pharmaceuticals (REGN) reported other non-current liabilities of $2.13B in Q1 2026.
- How has Regeneron Pharmaceuticals's other non-current liabilities changed year-over-year?
- Regeneron Pharmaceuticals's other non-current liabilities increased by 27.0% year-over-year, from $1.67B to $2.13B.
- What is the long-term trend for Regeneron Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's other non-current liabilities has grown at a 24.1% compound annual growth rate (CAGR), from $687.10M to $2.02B.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.